Catalyst Pharmaceuticals (CPRX) News Today $21.63 -0.42 (-1.92%) Closing price 03:59 PM EasternExtended Trading$21.75 +0.12 (+0.57%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of "Buy" by BrokeragesShares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been assigned an average recommendation of "Buy" from the nine research firms that are covering the firm, Marketbeat reports. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating toFebruary 20 at 4:11 AM | marketbeat.comCatalyst Pharmaceuticals (CPRX) Projected to Post Quarterly Earnings on WednesdayCatalyst Pharmaceuticals (NASDAQ:CPRX) will be releasing earnings after the market closes on Wednesday, February 26. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638181)February 19 at 4:28 AM | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stake Raised by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC boosted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 13.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 417,332February 19 at 3:38 AM | marketbeat.comThose who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) five years ago are up 374%February 17, 2025 | finance.yahoo.comCatalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025February 12, 2025 | globenewswire.comAdvisors Preferred LLC Purchases New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Advisors Preferred LLC purchased a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 50,171 shares of the biopharmaceutical company's stoFebruary 8, 2025 | marketbeat.comabrdn plc Purchases Shares of 484,666 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)abrdn plc purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 484,666 shares of the biopharmaceutical company's stock, valued at approximatelyFebruary 8, 2025 | marketbeat.comSpire Wealth Management Increases Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Spire Wealth Management raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1,342.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 14,429 shares of the biopharmaceutical company's stock after acquiring an additional 13,429 sharFebruary 7, 2025 | marketbeat.comBaird Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Outperform RecommendationFebruary 5, 2025 | msn.comBaird R W Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to "Strong-Buy"Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday.February 5, 2025 | marketbeat.comBaird starts Catalyst Pharma with Outperform, $28 targetFebruary 4, 2025 | msn.comRobert W. Baird Initiates Coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX)Robert W. Baird initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Tuesday. They set an "outperform" rating and a $28.00 price target on the stock.February 4, 2025 | marketbeat.comCatalyst Pharmaceuticals initiated with an Outperform at BairdFebruary 4, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest UpdateCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 6,680,000 shares, an increase of 12.5% from the December 31st total of 5,940,000 shares. Based on an average trading volume of 975,100 shares, the short-interest ratio is currently 6.9 days.February 3, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by SG Americas Securities LLCSG Americas Securities LLC lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 276.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,812 shares of theJanuary 31, 2025 | marketbeat.comCatalyst Pharmaceuticals stock hits all-time high of $24.44January 30, 2025 | msn.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 1-Year High - Still a Buy?Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 12-Month High - Time to Buy?January 30, 2025 | marketbeat.comEMC Capital Management Purchases 12,340 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)EMC Capital Management grew its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 509.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,761 shares oJanuary 30, 2025 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Shares Up 5.4% - Time to Buy?Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Up 5.4% - Here's WhyJanuary 29, 2025 | marketbeat.comMoody Aldrich Partners LLC Sells 60,990 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Moody Aldrich Partners LLC lowered its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 22.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 215,657 shares of the biopharmaceutical company'January 29, 2025 | marketbeat.comNilsine Partners LLC Invests $700,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Nilsine Partners LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 33,519 shares of the biopharmaceutical company'sJanuary 29, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Pacer Advisors Inc.Pacer Advisors Inc. raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 5.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,955,508 shares of the biopharmaceuticalJanuary 28, 2025 | marketbeat.comDakota Wealth Management Makes New $236,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Dakota Wealth Management acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 11,320 shares of the biopharmaceutical compaJanuary 27, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of "Buy" from AnalystsShares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been given an average recommendation of "Buy" by the seven ratings firms that are currently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12-montJanuary 26, 2025 | marketbeat.comCatalyst Pharmaceuticals board member to retireJanuary 24, 2025 | msn.comCatalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap CompaniesJanuary 23, 2025 | globenewswire.comCatalyst announces sub-licensee pharma launches FIRDAPSE in JapanJanuary 21, 2025 | markets.businessinsider.comOppenheimer maintains Catalyst stock Outperform with $31 targetJanuary 21, 2025 | msn.comFIRDAPSE now available in Japan for muscle weaknessJanuary 21, 2025 | msn.comCatalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in JapanJanuary 21, 2025 | globenewswire.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Up 12.5% in DecemberCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 6,680,000 shares, a growth of 12.5% from the December 15th total of 5,940,000 shares. Based on an average daily trading volume, of 975,100 shares, the short-interest ratio is currently 6.9 days.January 18, 2025 | marketbeat.com61,009 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by Redhawk Wealth Advisors Inc.Redhawk Wealth Advisors Inc. acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 61,009 shares of the biopharmaceutical compJanuary 16, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)JPMorgan Chase & Co. boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 9.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 408,261 shares of the biopharmaceuticaJanuary 15, 2025 | marketbeat.comCatalyst Pharma (CPRX) Receives a Buy from Truist FinancialJanuary 14, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gainsJanuary 13, 2025 | marketwatch.comCatalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSEJanuary 13, 2025 | seekingalpha.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Stock Rating Lowered by StockNews.comStockNews.com lowered shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday.January 11, 2025 | marketbeat.comCatalyst Pharmaceuticals price target raised to $35 from $30 at H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals price target raised to $31 from $29 at OppenheimerJanuary 10, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright raised their target price on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a research report on Friday.January 10, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Teva PharmaceuticalsJanuary 9, 2025 | finanznachrichten.deCatalyst settlement with Teva a positive event, says BofAJanuary 9, 2025 | markets.businessinsider.comBank of America Reaffirms Buy Rating for Catalyst Pharmaceuticals (NASDAQ:CPRX)Bank of America reissued a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday.January 9, 2025 | marketbeat.comCatalyst Pharmaceuticals Secures Patent Victory: Analyst Reaffirms Buy Rating with 58.7% Upside PotentialJanuary 9, 2025 | markets.businessinsider.comCatalyst Pharmaceuticals reports settlement of Firdapse patent litigation with TevaJanuary 8, 2025 | markets.businessinsider.comCatalyst stock climbs 15% on Firdapse litigation settlementJanuary 8, 2025 | msn.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Trading Up 13% - Should You Buy?Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 13% Higher - Still a Buy?January 8, 2025 | marketbeat.comCatalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva PharmaceuticalsJanuary 8, 2025 | globenewswire.comCatalyst Pharmaceuticals management to meet with TruistJanuary 8, 2025 | markets.businessinsider.comOliver Luxxe Assets LLC Purchases 35,225 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Oliver Luxxe Assets LLC boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 103.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 69,250 shares of the biopharmaceutical company's stJanuary 7, 2025 | marketbeat.com Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Media Mentions By Week CPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CPRX News Sentiment▼0.650.60▲Average Medical News Sentiment CPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CPRX Articles This Week▼45▲CPRX Articles Average Week Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PCVX News SRPT News QGEN News ASND News ROIV News RVMD News LEGN News BBIO News AXSM News BPMC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CPRX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CPRX Stock Alerts